The other path for follow-ons.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 18612272.
- Also identified by DOI 10.1038/nbt0708-715.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
With follow-on biologics essentially dead in the water in the US, the decision of the world's largest generics manufacturer to invest in a platform for enhancing protein pharmacokinetics could pay dividends.
Medical subject headings
- Biopharmaceutics
- Drug Industry
- Drugs, Generic
- Therapeutic Equivalency